Back

Why atrial fibrillation duration should be an endpoint in atrial fibrillation ablation trials

31 August 2024 (14:00 - 14:15)
Organised by: Logo
Congress Presentation Part of: Management of atrial fibrillation: knowns and unknowns Treatment ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Madelene Carina Blomstrom-Lundqvist

Orebro University Hospital, Orebro (Sweden)

4 More presentations in this session

Presentation thumbnail
The three pillars of atrial fibrillation management
Professor G. Lip (Liverpool, GB)
Slides Video
Presentation thumbnail
Will left atrial appendage occlusion replace oral anticoagulation?
Professor M. Glikson (Jerusalem, IL)
Slides Video
Presentation thumbnail
Pulsed field ablation: should it replace radiofrequency and balloon cryoablation?
Doctor T. De Potter (Aalst, BE)
Slides Video
Presentation thumbnail
Management of atrial fibrillation: knowns and unknowns - discussion
Video

Access the full session

Session thumbnail
Management of atrial fibrillation: knowns and unknowns
Video

The Event

Event poster

ESC Congress 2024

31 August 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Atrial fibrillation burden as efficacy endpoint for atrial fibrillation ablation: strengths and weaknesses of implementation
thumbnail
Congress Presentation
Atrial fibrillation burden should be the primary outcome in rhythm control trials: pro
thumbnail
Congress Presentation
Evolving concepts in atrial fibrillation: classification, burden, and key trial endpoints

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources